SEOM clinical guidelines for cervical cancer (2019)

• A. de Juan ^[1] ; A. Redondo ^[2] ; M. J. Rubio ^[3] ; Y. García ^[8] ; J. Cueva ^[4] ; L. Gaba ^[9] ; A. Yubero ^[5] ; J. Alarcón ^[6] ; C. Maximiano ^[7] ; A. Oaknin ^[10]
  1. [1] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  2. [2] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  3. [3] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  4. [4] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  5. [5] Hospital Clínico Universitario Lozano Blesa

     Hospital Clínico Universitario Lozano Blesa

     Zaragoza, España

     
  6. [6] Hospital Universitario Son Espases

     Hospital Universitario Son Espases

     Palma de Mallorca, España

     
  7. [7] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  8. [8] Parc Taulí Hospital Universitari
  9. [9] Hospital Clinic i Provincial de Barcelona
  10. [10] Hospital Universitario Vall d’Hebron

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 2 (February), 2020 (Ejemplar dedicado a: Clinical Guides in Oncology), págs. 270-278
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, the screening programs have dramatically decreased the incidence of CC; however, the lack of accessibility to them in developing countries makes CC an important cause of mortality. Clinical stage is the most relevant prognostic factor in CC. The new FIGO staging system published in 2018 is more accurate than the previous one since it takes into account the lymph node status. In early stages, the primary treatment is surgery—with some concerns recently raised regarding minimally invasive surgery because it might decrease survival—or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. For recurrent or metastatic CC, the combination of chemotherapy plus bevacizumab is the preferred therapy. Immunotherapy approach based on checkpoint inhibitors is evolving as the election therapy following failure to platinum therapy.